Prophylactic HPV vaccines reduce recurrence rates after conization of CIN: a clinical research review

Cervical conization serves as the primary and effective treatment for high-grade squamous intraepithelial lesions (HSIL). Following conization, recurrence of cervical intraepithelial neoplasia (CIN) and persistent human papillomavirus (HPV) infection remain key factors contributing to the onset and progression of cervical cancer. Current evidence indicates that prophylactic HPV vaccination in HSIL/CIN2+ patients significantly reduces recurrence rates, thus lowering the risk of complications from repeat treatments. This strategy successfully integrates both primary and secondary prevention, broadening the clinical application of HPV vaccination. This review consolidates data from existing clinical studies and proposes directions for future research to inform post-conization management of HSIL.

Prophylactic HPV vaccine; Conization; CIN; Recurrence; Clinical studies

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73: 17–48.

[2] Castle PE. Looking back, moving forward: challenges and opportunities for global cervical cancer prevention and control. Viruses. 2024; 16: 1357.

[3] Branch of Cancer Prevention and Control, Chinese Preventive Medicine Association; Chinese Obstetrics and Gynecology Association Colposcopy and Cervical Neoplasia Committee; Chinese Society of Colposcopy and Cervical Pathology of China Health Birth Science Association; Beijing Medical Doctor (Technician) Society of Laboratory Medicine. Chinese expert consensus on the use of human papillomavirus nucleic acid testing for cervical cancer screening (2022). Chinese Medical Journal. 2023; 103: 1184–1195. (In Chinese)

[4] Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease. 2020; 24: 102–131.

[5] Fan A, Wang C, Han C, Wang Y, Xue F, Zhang L. Factors affecting residual/recurrent cervical intraepithelial neoplasia after cervical conization with negative margins. Journal of Medical Virology. 2018; 90: 1541–1548.

[6] Cassani C, Dominoni M, Pasquali MF, Gardella B, Spinillo A. The role of multiple high-risk human papillomavirus infection on the persistence recurrence of high-grade cervical lesions after standard treatment: a systematic review and a meta-analysis. Acta Obstetricia et Gynecologica Scandinavica. 2024; 103: 1028–1035.

[7] Wang J, Wang C, Su T. Risk factors for residual lesions after total hysterectomy in patients with high-grade cervical intraepithelial neoplasia. BMC Women’s Health. 2024; 24: 369.

[8] De Vuyst H, Mugo NR, Franceschi S, McKenzie K, Tenet V, Njoroge J, et al. Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya. PLOS ONE. 2014; 9: e111037.

[9] Kulkarni A, Covens A, Durand N, Ghorab Z, Gien LT, Osborne R, et al. Role of HPV in the prediction of persistence/recurrence after treatment for cervical precancer. Journal of Obstetrics and Gynaecology Canada. 2023; 45: 102171.

[10] Markowitz LE, Naleway AL, Lewis RM, Crane B, Querec TD, Weinmann S, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination. Vaccine. 2019; 37: 3918–3924.

[11] Yoon D, Lee JH, Lee H, Shin JY. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. The BMJ. 2021; 372: m4931.

[12] Combita AL, Reyes V, Puerto D, Murillo R, Sánchez R, Nuñez M, et al. Reduction in vaccine HPV type infections in a young women group (18–25 years) five years after HPV vaccine introduction in Colombia. Cancer Prevention Research. 2022; 15: 55–66.

[13] Kechagias KS, Kalliala I, Bowden SJ, Athanasiou A, Paraskevaidi M, Paraskevaidis E, et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. The BMJ. 2022; 378: e070135.

[14] Eriksen DO, Jensen PT, Schroll JB, Hammer A. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: a systematic review and meta-analysis. Acta Obstetricia et Gynecologica Scandinavica. 2022; 101: 597–607.

[15] Di Donato V, Caruso G, Petrillo M, Kontopantelis E, Palaia I, Perniola G, et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. Vaccines. 2021; 9: 410.

[16] Martinez-Gomez X, Curran A, Campins M, Alemany L, Rodrigo-Pendas JA, Borruel N, et al. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Euro Surveillance. 2019; 24: 1700857.

[17] Cho HW, Min KJ, Kwon SH, Kim K, Kim S, Seong SJ, et al. Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines. Journal of Gynecologic Oncology. 2021; 32: e94.

[18] Williamson AL. Recent developments in human papillomavirus (HPV) Vaccinology. Viruses. 2023; 15: 1440.

[19] Yokoji K, Giguere K, Malagon T, Ronn MM, Mayaud P, Kelly H, et al. Association of naturally acquired type-specific HPV antibodies and subsequent HPV re-detection: systematic review and meta-analysis. Infectious Agents and Cancer. 2023; 18: 70.

[20] Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, et al. Prophylactic and therapeutic HPV vaccines: current scenario and perspectives. Frontiers in Cellular and Infection Microbiology. 2022; 12: 909223.

[21] Saftlas AF, Spracklen CN, Ryckman KK, Stockdale CK, Penrose K, Ault K, et al. Influence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions. Journal of Reproductive Immunology. 2015; 109: 74–83.

[22] Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009; 384: 410–414.

[23] Zhai F, Mu S, Song Y, Zhang M, Zhang C, Lv Z. Associations between preoperative inflammatory indices and residual or recurrent cervical intraepithelial neoplasia post loop electrosurgical excision procedure. Journal of Inflammation Research. 2024; 17: 8741–8751.

[24] Velentzis LS, Brotherton JML, Canfell K. Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric. 2019; 22: 596–602.

[25] Ding T, Li L, Duan R, Chen Y, Yang B, Xi M. Risk factors analysis of recurrent disease after treatment with a loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia. International Journal of Gynaecology and Obstetrics. 2023; 160: 538–547.

[26] Tortellini E, Fosso Ngangue YC, Dominelli F, Guardiani M, Falvino C, Mengoni F, et al. Immunogenicity and efficacy of vaccination in people living with human immunodeficiency virus. Viruses. 2023; 15: 1844.

[27] Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. American Journal of Obstetrics and Gynecology. 2016; 215: 212.e1–212.e15.

[28] Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, et al. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. Human Vaccines & Immunotherapeutics. 2022; 18: 2105067.

[29] Wang J, Peng Y, Xu H, Cui Z, Williams RO III. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech. 2020; 21: 225.

[30] Watson-Jones D, Changalucha J, Whitworth H, Pinto L, Mutani P, Indangasi J, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet. Global Health. 2022; 10: e1473–e1484.

[31] Yang J, Xue F. Research progress of immune mechanisms related to persistent HPV infection in CIN after cervical conization. Iranian Journal of Allergy, Asthma, and Immunology. 2024; 23: 467–475.

[32] Chang H, Hong JH, Lee JK, Cho HW, Ouh YT, Min KJ, et al. Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization. Journal of Gynecologic Oncology. 2018; 29: e27.

[33] Sundaram ME, Kieke BA, Hanson KE, Belongia EA, Weintraub ES, Daley MF, et al. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Human Vaccines & Immunotherapeutics. 2022; 18: 2159215.

[34] World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. 2022. Available at: https://www.who.int (Accessed: 08 October 2024).

[35] Arredondo JL, Villagomez Martinez SM, Concepcion Morales M, Meyer S, Toh ML, Zocchetti C, et al. Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico. Vaccine. 2021; 39: 3388–3396.

[36] Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajden M, et al. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9–10 year-old girls according to 0–6 month schedule. Human Vaccines & Immunotherapeutics. 2014; 10: 2438–2445.

[37] Sull M, Eavey J, Papadouka V, Mandell R, Hansen MA, Zucker JR. Adolescent vaccine co-administration and coverage in New York City: 2007–2013. Pediatrics. 2014; 134: e1576–e1583.

[38] Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. The BMJ. 2012; 344: e1401.

[39] Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow SN, et al.; HPV PATRICIA Study Group. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial. International Journal of Cancer. 2016; 139: 2812–2826.

[40] Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? Gynecologic Oncology. 2013; 130: 264–268.

[41] Gómez de la Rosa AG, Quesada López-Fe A, Vilar Chesa M, Ferrer Machín A, Gimeno Gil A, Molina Bethancourt A, et al. Efficacy of human papillomavirus vaccination 4 years after conization for high-grade cervical neoplasia. Journal of Lower Genital Tract Disease. 2021; 25: 287–290.

[42] Casajuana-Pérez A, Ramírez-Mena M, Ruipérez-Pacheco E, Gil-Prados I, García-Santos J, Bellón-Del Amo M, et al. Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL/CIN 2–3: the VENUS study. Vaccines. 2022; 10: 288.

[43] Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. International Journal of Cancer. 2020; 147: 641–647.

[44] Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecologic Oncology. 2018; 151: 229–234.

[45] Del Pino M, Martí C, Torras I, Henere C, Munmany M, Marimon L, et al. HPV vaccination as adjuvant to conization in women with cervical intraepithelial neoplasia: a study under real-life conditions. Vaccines. 2020; 8: 245.

[46] Petrillo M, Dessole M, Tinacci E, Saderi L, Muresu N, Capobianco G, et al. Efficacy of HPV vaccination in women receiving LEEP for cervical dysplasia: a single institution’s experience. Vaccines. 2020; 8: 45.

[47] Chen M, Li C, Cui Q, Zhou C, Chen P, Yao S. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: a prospective observational study in China. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2023; 286: 10–15.

[48] Pieralli A, Bianchi C, Auzzi N, Fallani MG, Bussani C, Fambrini M, et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease. Archives of Gynecology and Obstetrics. 2018; 298: 1205–1210.

[49] Firnhaber C, Swarts A, Jezile V, Mulongo M, Goeieman B, Williams S, et al. Human papillomavirus vaccination prior to loop electroexcision procedure does not prevent recurrent cervical high-grade squamous intraepithelial lesions in women living with human immunodeficiency virus: a randomized, double-blind, placebo-controlled trial. Clinical Infectious Diseases. 2021; 73: e2211–e2216.

[50] van de Laar RLO, Hofhuis W, Duijnhoven RG, Polinder S, Melchers WJG, van Kemenade FJ, et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. BMC Cancer. 2020; 20: 539.

[51] Bogani G, Raspagliesi F, Sopracordevole F, Ciavattini A, Ghelardi A, Simoncini T, et al. Assessing the long-term role of vaccination against HPV after loop electrosurgical excision procedure (LEEP): a propensity-score matched comparison. Vaccines. 2020; 8: 717.

[52] Johnson Jones ML, Gargano JW, Powell M, Park IU, Niccolai LM, Bennett NM, et al. Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18. American Journal of Epidemiology. 2020; 189: 265–276.

[53] Jentschke M, Kampers J, Becker J, Sibbertsen P, Hillemanns P. Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine. 2020; 38: 6402–6409.

[54] Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. The Lancet. Oncology. 2021; 22: 1518–1529.

[55] Kreimer AR, Sampson JN, Porras C, Schiller JT, Kemp T, Herrero R, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. Journal of the National Cancer Institute. 2020; 112: 1038–1046.

[56] Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study. Clinical Infectious Diseases. 2020; 70: 608–614.

[57] Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evidence. 2022; 1: EVIDoa2100056.

[58] Panicker G, Rajbhandari I, Pathak HN, Brady AM, Unger ER. Multiplex immunoassay to measure antibody response to nine HPV vaccine types. Journal of Immunological Methods. 2021; 498: 113136.

[59] Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2023; 41: 236–245.

[60] Rodriguez AM, Zeybek B, Vaughn M, Westra J, Kaul S, Montealegre JR, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study. Cancer. 2020; 126: 1656–1667.

[61] Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016; 188: E281–E288.

[62] Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. The BMJ. 2014; 348: g1458.

[63] Dehlendorff C, Sparén P, Baldur-Felskov B, Herweijer E, Arnheim-Dahlström L, Ploner A, et al. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions. Vaccine. 2018; 36: 6373–6378.

[64] Brotherton JM, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, et al. Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis. Papillomavirus research. 2019; 8: 100177.

[65] Silverberg MJ, Leyden WA, Lam JO, Gregorich SE, Huchko MJ, Kulasingam S, et al. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. The Lancet. Child & Adolescent Health. 2018; 2: 707–714.

[66] Przybylski M, Pruski D, Millert-Kalinska S, Zmaczynski A, Baran R, Horbaczewska A, et al. Remission of HPV infection after LEEP-conization-a retrospective study. Ginekologia Polska. 2022; 93: 99–104.

[67] Iida Y, Sato S, Okawa M, Hikino K, Komatsu H, Kudoh A, et al. Prognostic value of human papillomavirus genotyping before and after cervical conization for squamous intraepithelial lesion. Acta Cytologica. 2023; 67: 17–26.

[68] Bogani G, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, Vercellini P, et al. HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: a focus on the potential role of vaccination. Tumori Journal. 2024; 110: 139–145.